Payers Reluctant To Leverage Comparative Effectiveness To Deny Coverage
This article was originally published in The Gray Sheet
Executive Summary
Just learning about the results of comparative studies does not move payers to deny coverage of targeted services based on the experiences so far of the New England Comparative Effectiveness Public Advisory Council.
You may also be interested in...
Effort Launches To Adapt Federal CER Research For New England Use
An ambitious effort is gearing up to adapt federal comparative effectiveness research into an easy-to-understand and useful tool for New England payers, providers, patients and policy-makers.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.